1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Clinical and radiologic characteristics of the study population^{^a}
Characteristic Linear GBCA–Exposed Children Macrocyclic GBCA–Exposed Children GBCA-Naive Control Subjects
Age (yr) 
    Mean (SD) 8.2 (SD, 5.4) 8.2 (SD, 5.1) 8.2 (SD, 3.6)
    Range 2–18 2–18 2–18
Sex 
    Male 23 23 23
    Female 10 10 10
Mean (SD) No. of contrast-enhanced MR imaging 2.4 (SD, 2.4) 4.03 (SD, 2.9) 0
Mean (SD) time interval between MR imaging (mo) 7.16 (SD, 7.5) 7.4 (SD, 7.3) 0
Mean (SD) accumulated gadolinium dose (mmol) 17.5 (SD, 24.1) 13.3 (SD, 11.9) 0
Diagnosis 
    Intracranial neoplasm 7 7 10
    Extracranial neoplasm 2 0 1
    Pituitary abnormality 3 6 2
    Orbit/optic nerve pathology 6 7 2
    Adrenoleukodystrophy 5 5 10
    Benign conditions 10 8 8
History of radiation treatment 3 2 3
History of chemotherapy 6 5 4
History of neurosurgery 2 2 3
↵a Data are number of patients unless indicated otherwise and mean (SD).